Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONUL vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
FDA: Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders.,Off-label: Management of hyperammonemia due to other causes (e.g., valproate toxicity, organic acidemias).
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Phenylacetate: 0.5-1 hour; phenylacetylglutamine: 1-2 hours. Clinical context: rapid clearance; requires continuous IV infusion for sustained effect.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Sodium phenylacetate is metabolized via conjugation with glutamine (by glutamine N-phenylacetyltransferase) to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine (by benzoyl-Co A:glycine N-acyltransferase) to form hippurate. Both conjugates are rapidly excreted by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >80% (primarily as phenylacetylglutamine). Biliary/fecal: <5%.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Phenylacetate: 82% bound to albumin; phenylacetylglutamine: 51% bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Phenylacetate: 0.3-0.5 L/kg; phenylacetylglutamine: 0.1-0.2 L/kg. Indicates distribution primarily in extracellular fluid.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: Not available; sodium phenylacetate/sodium benzoate is administered intravenously only.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Contraindicated in severe renal insufficiency (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min): reduce dose by 50%. For mild impairment (Cr Cl 50-80 m L/min): no adjustment needed.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific guidelines based on Child-Pugh; use with caution in severe hepatic impairment. Monitor ammonia levels.
No dosage adjustment required for hepatic impairment.
Same weight-based area (2.5 g/m²) as adults. For neonates and infants, dosage calculated per body surface area. Administration route and frequency identical to adults.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
No specific dose adjustment; use caution due to age-related renal decline. Monitor renal function and ammonia levels.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Ammonul must be administered with arginine to prevent arginine deficiency and worsening hyperammonemia. Neurotoxicity (including seizures, cerebral edema, and death) may occur if not properly monitored. Extravasation can cause severe tissue necrosis; ensure proper IV access.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Monitor plasma ammonia levels, electrolytes, and blood counts closely.,Risk of hypernatremia (high sodium load); adjust fluid and sodium intake.,Extravasation risk: administer through a central line if possible; treat extravasation immediately.,May cause hyperventilation and metabolic acidosis.,Use with caution in patients with hepatic or renal impairment.,Contains sodium benzoate; possible hypersensitivity reactions.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Known hypersensitivity to any component of Ammonul.,Pre-existing severe hypernatremia.,Concomitant use with other drugs containing sodium benzoate or sodium phenylacetate.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Take with food or meals to reduce gastrointestinal distress. Avoid high-protein supplements or foods that may increase ammonia levels; dietary protein restriction should be managed by a dietitian.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential risk unknown; second/third trimester: may cause maternal ammonia accumulation if subtherapeutic, but drug is essential for urea cycle disorders. Risk of untreated hyperammonemia outweighs potential teratogenic risk.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
No human data on excretion in breast milk; M/P ratio unknown. Caution advised; consider risk of infant hyperammonemia vs. benefit of breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Monitor ammonia levels closely; pregnancy may increase metabolic demands. Dose adjustments based on ammonia levels: usual dose is weight-based (e.g., 5.5 g/m²/day for sodium phenylacetate/sodium benzoate). Consider increased clearance during pregnancy? No specific data; empiric adjustments based on ammonia levels recommended.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
AMMONUL (sodium phenylbutyrate) is used as a nitrogen-binding agent in urea cycle disorders. Monitor plasma ammonia levels closely; target <60 μmol/L. Administer with food to reduce GI irritation. Not recommended in patients with severe hepatic impairment due to reduced conversion to phenylacetate. Contraindicated in pregnancy (category C).
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Take exactly as prescribed; do not skip doses.,May cause nausea, vomiting, or diarrhea; take with food.,Avoid use of valproic acid or corticosteroids unless directed.,Contact provider if symptoms of hyperammonemia occur (vomiting, lethargy, confusion).,Women of childbearing potential should use effective contraception.,Store at room temperature away from moisture.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
No interactions on record
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONUL vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
AMMONUL is a Ammonia Detoxicant that works by Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONUL and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONUL is: For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONUL and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONUL is classified as Category C. Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.